Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Reform's "Sunshine" Clause Prompts Firms To Review Disclosure Web Sites

Executive Summary

Any drug, device or medical supply company that sells products to a government program and provides payments or items worth more than $10 to practicing physicians or teaching hospitals will be required to post those outlays in a publicly-available database starting in 2013

You may also be interested in...



Sunshine Act Payment Comparisons Likely Cloudy Due To Disclosure Judgment Calls

Some answers to industry questions about ambiguity in sunshine regulations may come through enforcement actions, Sidley Austin’s James Stansel says.

“Sunshine” Might Bring Public Awareness Campaign On Medical Research

Final CMS reg on reporting industry payments to physicians include limiting coverage to companies operating in the U.S. and a definition of third-party payments; despite wins in the revisions from the proposed rule, industry may need a widespread education campaign in order to preserve the value of its physician relationships.

Sunshine Proposal Allows Lump Sum Reporting Of Research Payments To Institutions

CMS-proposed rule would allow companies to report a single figure for research payments to institutions and attribute it to the principal investigator(s), although the agency will not include it when computing physicians’ total receipts from industry. The agency wants more details on what payments are for, calling on firms to break them down by category when more than one expense type is included in a single payment.

Related Content

Topics

UsernamePublicRestriction

Register

PS052166

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel